Notification That Annual Report Will Be Submitted Late (nt 10-k)
March 31 2022 - 4:01PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
12b-25
Commission
File Number: 000-53166
NOTIFICATION
OF LATE FILING
☒
Form 10-K |
☐
Form 20-F |
☐
Form 11-K |
☐ Form 10-Q |
☐
Form 10-D |
☐
Form N-SAR |
☐ Form N-CSR |
|
For
Period Ended: December 31, 2021
☐Transition Report on Form 10-K |
☐
Transition Report on Form 10-Q |
☐
Transition Report on Form 20-F |
☐
Transition Report on Form N-SAR |
☐
Transition Report on Form 11-K |
|
For
the Transition Period Ended: _______________________________________
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein.
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: _______________________________________
PART
I
REGISTRANT
INFORMATION
Full
name of registrant |
MusclePharm
Corporation |
Former
name if applicable |
|
Address
of principal executive office |
6728
W. Sunset Rd., Suite 130 |
City,
state and zip code |
Las
Vegas, NV 89118 |
PART
II
RULE
12b-25 (b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25
(b), the following should be completed. (Check box if appropriate.)
|
(a) |
The
reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
☒
|
(b) |
The
subject annual report, semi-annual report, transition report on Form 10-K, 20-F, 11-K or Form N-SAR or Form N-CSR, or portion thereof
will be filed on or before the 15th calendar day following the prescribed due date or the subject quarterly report or
transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth
calendar day following the prescribed due date; and |
|
(c) |
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART
III
NARRATIVE
State
below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR, N-CSR, or the transition report portion thereof, could
not be filed within the prescribed time period.
The
Company is unable to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 within the prescribed time period
because additional time is required to finalize its financial statements to be filed as part of the Form 10-K. The Company expects to
file the Form 10-K within the extension period of 15 calendar days.
PART
IV
OTHER
INFORMATION
(1)
Name and telephone number of person to contact in regard to this notification
Sabina
Rizvi |
|
(800) |
|
292-3909 |
(Name) |
|
(Area
Code) |
|
(Telephone
Number) |
(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s)
been filed? If the answer is no, identify report(s).
☒
Yes ☐ No
(3)
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or portion thereof?
☐ Yes
☒ No
If
so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why
a reasonable estimate of the results cannot be made.
MusclePharm
Corporation
(Name
of Registrant as Specified in Charter)
Has
caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
Dated:
March 31, 2022 |
|
/s/
Sabina Rizvi |
|
By: |
Sabina
Rizvi |
|
Title: |
Chief
Financial Officer |
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Jul 2024 to Aug 2024
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Aug 2023 to Aug 2024